National Graphite Corp. (NGRC)
NGRC Stock Price Chart
Explore National Graphite Corp. interactive price chart. Choose custom timeframes to analyze NGRC price movements and trends.
NGRC Company Profile
Discover essential business fundamentals and corporate details for National Graphite Corp. (NGRC) to support your stock research and investment decisions.
Sector
Financial Services
Industry
Shell Companies
IPO Date
3 Aug 2012
Employees
1.00
CEO
Ulrike Dickmann
Description
National Graphite Corp., through its subsidiary, Biotech Development Corp., operates as a biopharmaceutical risk/cost-sharing company. The company collaborates with clinical stage companies that develop new biological entities or new therapeutically platforms for the treatment of various diseases, rare diseases, and diseases with unmet needs. It is developing a drug candidate called ELAFIN, which is a human identic protein for the treatment of postoperative inflammatory complications. National Graphite Corp. has a collaboration agreement with Proteo Inc. for developing ELAFIN. The company was formerly known as Lucky Boy Silver Corporation and changed its name to National Graphite Corp. in May 2012. National Graphite Corp. was founded in 2006 and is based in Duesseldorf, Germany.
NGRC Financial Timeline
Browse a chronological timeline of National Graphite Corp. corporate events including earnings releases, dividend announcements, and stock splits.
NGRC Stock Performance
Access detailed NGRC performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.